STOCK TITAN

Beyondspring Inc Stock Price, News & Analysis

BYSI Nasdaq

Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.

BeyondSpring Inc (NASDAQ: BYSI) is a clinical-stage biopharmaceutical leader advancing innovative cancer therapies through its Plinabulin pipeline and target protein degradation research. This page serves as the definitive source for verified company updates, providing investors and researchers with essential insights into therapeutic developments and strategic initiatives.

Access timely announcements spanning clinical trial progress, regulatory milestones, and partnership agreements. Our curated collection includes press releases on Plinabulin's multifaceted mechanism of action, updates from global Phase 3 studies, and innovations from the SEED Therapeutics collaboration. Each update is vetted for accuracy to support informed decision-making.

Bookmark this resource for structured access to BeyondSpring's scientific advancements in immuno-oncology and protein degradation technology. Regular updates ensure you maintain current awareness of the company's progress in addressing unmet needs in NSCLC and other oncology indications.

Rhea-AI Summary

BeyondSpring (NASDAQ: BYSI) announced significant findings from its DUBLIN-3 Phase 3 trial of plinabulin, showing improved survival rates for NSCLC patients. Compared to docetaxel alone, the combination with plinabulin demonstrated enhanced overall survival, overall response rate, and progression-free survival, alongside a reduction in severe neutropenia incidents. The findings will be presented at the ESMO Congress on September 20, 2021. BeyondSpring plans to submit an NDA in the U.S. and China for plinabulin, furthering its regulatory journey for treating NSCLC and preventing chemotherapy-induced neutropenia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.48%
Tags
-
Rhea-AI Summary

BeyondSpring's subsidiary, Wanchunbulin, has formed a partnership with Hengrui Pharmaceuticals for the exclusive rights to commercialize and co-develop plinabulin in Greater China. The agreement includes milestone payments of up to 1.3 billion RMB (approx. $200 million), consisting of an upfront payment of 200 million RMB (about $30 million) and regulatory sales milestones. Hengrui will also make an equity investment of 100 million RMB (around $15 million) into Wanchunbulin. This collaboration focuses on the potential of plinabulin in treating chemotherapy-induced neutropenia and non-small cell lung cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.7%
Tags
none
-
Rhea-AI Summary

BeyondSpring (NASDAQ: BYSI) announced that CEO Dr. Lan Huang has been named one of the PharmaVOICE 100 most inspiring people in life sciences. This recognition highlights her leadership in developing plinabulin, a key oncology drug under FDA Priority Review for chemotherapy-induced neutropenia, with a PDUFA date set for November 30, 2021. Positive results from the DUBLIN-3 Phase 3 study showed improved survival rates for non-small cell lung cancer patients, supporting plans for a second NDA submission next year, potentially expanding plinabulin's indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.88%
Tags
none
Rhea-AI Summary

BeyondSpring announced positive topline results from the DUBLIN-3 trial, demonstrating that plinabulin combined with docetaxel significantly improves overall survival (mean OS, p = 0.03) for NSCLC patients compared to docetaxel alone. Key secondary endpoints also showed significant improvements in overall response rate, progression-free survival, and reduced incidence of Grade 4 neutropenia. The company intends to seek U.S. FDA and China NMPA approval based on these results, with full data set to be presented at an upcoming conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
176.01%
Tags
none
-
Rhea-AI Summary

BeyondSpring (NASDAQ: BYSI) appointed Brendan Delaney to its Board of Directors, effective immediately. Delaney brings over 25 years of experience in commercial oncology drug launches, which is crucial as BeyondSpring's lead asset, plinabulin, is under FDA Priority Review for preventing chemotherapy-induced neutropenia, with a PDUFA date set for November 30, 2021. His expertise is expected to aid in the commercial launch planning, contingent on regulatory approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Summary

BeyondSpring announced its participation in the virtual William Blair Biotech Focus Conference on July 14-15, 2021. The company, focused on innovative cancer therapies, will be available for one-on-one meetings during the event. Their lead asset, plinabulin, is under review for preventing chemotherapy-induced neutropenia, with a PDUFA date of November 30, 2021, in the U.S. BeyondSpring’s pipeline includes pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, utilizing a targeted protein degradation discovery platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
conferences
Rhea-AI Summary

BeyondSpring announced an R&D Day on June 25, 2021, to discuss its immune agent Plinabulin for cancer treatment, particularly in non-small cell lung cancer. Key Opinion Leaders Steven Lin, M.D., and Trevor Feinstein, M.D., will present insights on the current treatment landscape. Topics include Plinabulin's FDA priority review for chemotherapy-induced neutropenia and ongoing pivotal studies. The company aims to address unmet medical needs in cancer therapy, with Plinabulin being central to their strategy, also exploring combinations with checkpoint inhibitors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
conferences
-
Rhea-AI Summary

BeyondSpring announced significant advancements regarding its lead drug, plinabulin, including a New Drug Application (NDA) filed with the FDA for priority review aimed at preventing chemotherapy-induced neutropenia (CIN). The FDA set a PDUFA date of November 30, 2021. Recent presentations revealed favorable PROTECTIVE-2 Phase 3 data, indicating plinabulin combined with G-CSF offers better outcomes than pegfilgrastim alone. The company also initiated clinical trials on plinabulin with checkpoint inhibitors for resistant tumors, showcasing promising Phase 1 data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags
-
Rhea-AI Summary

BeyondSpring Inc. (NASDAQ: BYSI) will host a conference call on June 16, 2021, at 8:30 AM ET to discuss its Q1 2021 financial results and recent corporate updates. Investors can access the call by dialing 877-451-6152 (U.S.) or 201-389-0879 (International), using conference ID 13720525. A live webcast will be available on the company’s website, and an archived replay will be accessible for 90 days. BeyondSpring focuses on developing immuno-oncology therapies, with its lead asset, plinabulin, undergoing Priority Review for chemotherapy-induced neutropenia and being tested for anti-cancer benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences earnings
Rhea-AI Summary

BeyondSpring, a biopharmaceutical firm, showcased data from the PROTECTIVE-1 Phase 3 clinical trial of plinabulin at the ASCO Annual Meeting. Plinabulin demonstrated a non-inferior effectiveness against chemotherapy-induced neutropenia (CIN) compared to pegfilgrastim, with benefits including reduced febrile neutropenia and lower bone pain. The drug, which targets CIN prevention, received FDA's Priority Review for its NDA submission in the U.S. and China, with a PDUFA action date set for November 30, 2021. The study results highlighted plinabulin's fast action and potential market impact, especially amid rising CIN-related hospitalizations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags

FAQ

What is the current stock price of Beyondspring (BYSI)?

The current stock price of Beyondspring (BYSI) is $2.31 as of July 9, 2025.

What is the market cap of Beyondspring (BYSI)?

The market cap of Beyondspring (BYSI) is approximately 97.6M.
Beyondspring Inc

Nasdaq:BYSI

BYSI Rankings

BYSI Stock Data

97.57M
34.16M
15.21%
13.08%
4.74%
Biotechnology
Pharmaceutical Preparations
Link
United States
FLORHAM PARK